Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma - Concepedia

Concepedia

Publication | Closed Access

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

118

Citations

28

References

2014

Year

Ursula A. Matulonis, Ignace Vergote, Floor Backes, Lainie P. Martin, Scott McMeekin, Michael J. Birrer, Frank Campana, Yi Xu, Coumaran Égile, Sharad Ghamande

Gynecologic Oncology

Tumoral PathologyMedicineGynecologyPathologyPhase Ii StudyCancer TreatmentPi3k Inhibitor PilaralisibOncologyRadiation OncologyRecurrent Endometrial CarcinomaCancer ResearchCancer Growth

References

	Year	Citations

Page 1

Page 1